Poland· PL-100007743

Aspargin

A other mineral products product containing magnesii hydrogenoaspartas + kalii hydrogenoaspartas, registered in Poland by Farmaceutyczna Spółdzielnia Pracy FILOFARM. The same ATC class is registered in 4 of our 19 countries.

ATC A12CX

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedAsparginATCA12CXREGISTER NO.PL-100007743PACKS LISTED7CHECKEDSeptember 27, 2026

Where it is registered

Magnesii hydrogenoaspartas + kalii hydrogenoaspartas is registered in 4 of 19 countries.

Countries holding a registration under ATC A12CX (other mineral products), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 3 of them publish a price we can compare per daily dose

Magnesii hydrogenoaspartas + kalii hydrogenoaspartas · ATC A12CX

4 / 19 countries

  • Canada
  • Norwayprice
  • Polandprice
  • Switzerlandprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

URPL (Poland)
Active substance
Magnesii hydrogenoaspartas + Kalii hydrogenoaspartas
Manufacturer
Farmaceutyczna Spółdzielnia Pracy FILOFARM
Country
Poland (PL)
ATC code
A12CX
ATC class
Other mineral products
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 7

  • gtin
    05909990210718
  • gtin
    05909990212347
  • gtin
    05909990212354
  • gtin
    05909990210725
  • gtin
    05903270612360
  • gtin
    05903270612377
  • gtin
    05903270612384

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/226afd95-be46-4dd5-b6c6-2391c34948e3
GET /v1/drugs/226afd95-be46-4dd5-b6c6-2391c34948e3?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Tabletki",
  "source": "urpl",
  "strength": "250 mg + 250 mg (17 mg Mg 2+ + 54 mg K+)",
  "packaging": "05909990210718 ¦ OTC ¦ 1546\n50 tabl.\n05909990212347 ¦ OTC ¦ 25726\n25 tabl.\n05909990212354 ¦ OTC ¦ 26077\n75 tabl.\n05909990210725 ¦ OTC ¦ Skasowane ¦ 26080\n25 tabl.\n05903270612360 ¦ OTC ¦ 167403\n100 tabl.\n05903270612377 ¦ OTC ¦ 167404\n125 tabl.\n05903270612384 ¦ OTC ¦ 167405\n150 tabl.",
  "substance": "Magnesii hydrogenoaspartas 250 mg + Kalii hydrogenoaspartas 250 mg",
  "common_name": "Magnesii hydrogenoaspartas + Kalii hydrogenoaspartas",
  "pl_product_id": "100007743",
  "pozwolenie_nr": "02107",
  "auth_procedure": "NAR",
  "authorisation_validity": "Bezterminowe"
}

See everything about magnesii hydrogenoaspartas + kalii hydrogenoaspartas.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.